ArticleBlood2018
Polyreactive IgM initiates complement activation by PF4/heparin complexes through the classical pathway.
Article in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 48 citations in OpenAlex.
- Methods to Examine Complement Activation by HIT Immune Complexes.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Heparin: Over 100 Years of Anticoagulation.Handbook of experimental pharmacology · 2026Review
- NETosis and Neutrophil Activity Quantification in Pediatric Patients with Essential Thrombocythemia.International journal of molecular sciences · 2025Article
- Complement activation as a biomarker for platelet-activating antibodies in heparin-induced thrombocytopenia.Journal of thrombosis and haemostasis : JTH · 2025Article
- Divergent host humoral innate immune response to the smooth-to-rough adaptation ofFrontiers in cellular and infection microbiology · 2025Article
- Engineered IgM and IgG cleaving enzymes for mitigating antibody neutralization and complement activation in AAV gene transfer.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Thrombotic anti-PF4 immune disorders: HIT, VITT, and beyond.Hematology. American Society of Hematology. Education Program · 2023Article
- Novel Knowledge about Molecular Mechanisms of Heparin-Induced Thrombocytopenia Type II and Treatment Targets.International journal of molecular sciences · 2023Review
- Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia.Blood advances · 2022Article
- Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT).Seminars in hematology · 2022Article
- Natural antibodies and CRP drive anaphylatoxin production by urate crystals.Scientific reports · 2022Article
- Ex vivo observation of granulocyte activity during thrombus formation.BMC biology · 2022Article
- Article
- A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2.Blood advances · 2021Article
- Elucidation of Cellular Contributions to Heparin-Induced Thrombocytopenia Using Omic Approaches.Frontiers in pharmacology · 2021Review
- Autoimmunity elicited by the chemokine response to adenovirus vector vaccines may underlie vaccine-induced immune thrombotic thrombocytopaenia: a hypothesis.Clinical & translational immunology · 2021Article
- Pathogenesis of heparin-induced thrombocytopenia.Translational research : the journal of laboratory and clinical medicine · 2020Review
- Structural Features and PF4 Functions that Occur in Heparin-Induced Thrombocytopenia (HIT) Complicated by COVID-19.Antibodies (Basel, Switzerland) · 2020Review
- Targeting the Initiator Protease of the Classical Pathway of Complement Using Fragment-Based Drug Discovery.Molecules (Basel, Switzerland) · 2020Article
- Pathophysiology and Diagnosis of Drug-Induced Immune Thrombocytopenia.Journal of clinical medicine · 2020Review
Corrections and comments
- Commented on by
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
The mechanisms by which exposure to heparin initiates antibody responses in many, if not most, recipients are poorly understood. We recently demonstrated that antigenic platelet factor 4 (PF4)/heparin complexes activate complement in plasma and bind to B cells. Here, we describe how this process is initiated. We observed wide stable variation in complement activation when PF4/heparin was added to plasma of healthy donors, indicating a responder "phenotype" (high, intermediate, or low). Proteomic analysis of plasma from these healthy donors showed a strong correlation between complement activation and plasma immunoglobulin M (IgM) levels (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.